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ttp://dx.doi.org/10.1016/j.ajpath.2014.10.022Mitochondrial dynamics has recently become an area of piqued interest in neurodegenerative disorders,
including Parkinson disease (PD); however, the contribution of astrocytes to these disorders remains
unclear. Here, we show that the level of dynamin-like protein 1 (Dlp1; ofﬁcial name DNM1L), which
promotes mitochondrial ﬁssion, is lower in astrocytes from the brains of PD patients, and that decreased
astrocytic Dlp1 likely represents a relatively early event in PD pathogenesis. In support of this conclusion,
we show that Dlp1 knockdown dramatically affects mitochondrial morphological characteristics and
localization in astrocytes, impairs the ability of astrocytes to adequately protect neurons from the
excitotoxic effects of glutamate, and increases intracellular Ca2þ in response to extracellular glutamate,
resulting from compromised intracellular Ca2þ buffering. Taken together, our results suggest that
astrocytic mitochondrial Dlp1 is a key protein in mitochondrial dynamics and decreased Dlp1 may
interfere with neuron survival in PD by disrupting Ca2þ-coupled glutamate uptake. (Am J Pathol
2015, 185: 536e549; http://dx.doi.org/10.1016/j.ajpath.2014.10.022)Supported by NIH grants AG033398, ES004696-5897, ES007033-6364,
ES016873, ES019277, NS057567, NS060252, NS062684-6221,
NS082137 (J.Z.), and T32 ES007032 (J.G.H.), and National Institute of
Environmental Health Sciences grant T32 ES015459 (T.J.C. and T.S.).
Disclosures: None declared.Parkinson disease (PD) is a neurodegenerative disorder
clinically characterized by both motor and nonmotor
symptoms.1e3 The loss of dopaminergic (DAergic) neurons
in the substantia nigra pars compacta (SNpc) is the primary
cause of the motor deﬁcits,4 whereas nonmotor symptoms are
the result of dysfunction in multiple brain regions.2,3 Until
recently, most investigations have focused on the neuronal
pathogenesis. However, accumulating evidence shows that
astrocytes, which have multiple neuroprotective roles,5,6
contribute to neuronal loss in PD.7
Decreased respiratory chain activity8 and increased oxidative
damage in the SNpc9,10 contribute to neuronal demise in PD.
Among proteins that regulate mitochondrial functions,11 those
that regulate mitochondrial ﬁssion [dynamin-like protein 1
(Dlp1; ofﬁcial name DNM1L), ﬁssion 1], and fusion [(mitofu-
sins 1 and 2 and optic atrophy 1)] are particularly interesting.
Models of PD show dramatic effects in mitochondrial
morphological features, which can be rescued by altering
expression of these proteins.12,13 Our previous study proﬁled
the mitochondrial fraction of the SNpc in healthy control andstigative Pathology.
.PD patients and identiﬁed speciﬁc alterations in expression of
Dlp1, but not other mitochondrial ﬁssion and fusion proteins in
PD brains,14 suggesting Dlp1 plays a role in PD pathogenesis.
However, the cellular origin and consequences of decreased
Dlp1 expression remain to be fully elucidated.
A recent investigation found that Dlp1 potentially interacts
with the glutamate transporter 1 (GLT-1; ofﬁcial name
SLC1A2),15 which is speciﬁcally expressed by astrocytes,16
implicating this cell type in Dlp1-mediated pathogenic effects.
In theory, disrupting astrocyte regulation of extracellular gluta-
mate [also a function of the glutamate aspartate transporter
(GLAST; ofﬁcial name SLC1A317)] could result in excessive
extracellular glutamate. This excess glutamate could prolong the
opening of neuronal N-methyl-D-aspartate (NMDA) re-
ceptors,18 resulting in excessive Ca2þ entry and, ultimately,
Astrocytic Mitochondrial Dynamics in PDneuronal death. Indeed, this phenomenon of excitotoxicity has
been implicated in PD and animal models of PD,19,20 as well as
in other neurodegenerative diseases.
To test the hypothesis that decreased astrocytic Dlp1
expression contributes to neurodegeneration in PD, we
measured astrocytic and neuronal Dlp1 expression, in the
SNpc and cortex, in both PD and healthy control patients
and explored the molecular mechanisms related to astrocytic
dysfunction resulting from decreased Dlp1 expression.
Materials and Methods
Isolation of Mitochondria from Human Tissue
Mitochondria from frozen SNpc of healthy control and PD
patients were isolated, as previously described,14 and
resuspended in a buffer of 6 mol/L urea, 0.05% SDS, 5
mmol/L EDTA, and 50 mmol/L Tris-HCl (pH. 8.5). Protein
concentrations were determined by bicinchoninic acid assay
(Pierce, Rockford, IL), and 10 mg of protein was used for
Western blot analysis.
Western Blot Analysis
Transfected astrocytes were collected in radio-
immunoprecipitation assay buffer, sonicated on ice, and
centrifuged at 15,000  g for 10 minutes. The resulting su-
pernatant was collected as astrocyte protein sample, and con-
centrationwas determined by bicinchoninic acid assay. Protein
fromhuman tissueor astrocyteswas added toLammeli solution
(Biorad, Hercules, CA). For Dlp1 detection, Lammeli solution
had 2-mercaptoethanol andwas boiled for 5minutes. ForGLT-
1 or GLAST detection, 2-mercaptoethanol and boiling were
omitted. Proteins were separated by SDS-PAGE and trans-
ferred onto polyvinylidene diﬂuoride. Membranes were
blocked with 5% milk in Tris-buffered saline and Tween-20
(TBS-T). Primary antibodies were diluted in blocking buffer
[mouse anti-Dlp1, dilution 1:2000 (BD Biosciences, San Jose,
CA), mouse anti-excitatory amino-acid transporter (EAAT2),
dilution 1:1000 (Millipore, Billerica, MA), and rabbit anti-
EAAT1, dilution 1:1000 (Cell Signaling, Beverly, MA)].
Horseradish peroxidaseeconjugated secondary antibodies
diluted in 3%bovine serum albumin [BSA; anti-mouse or anti-
rabbit, dilution 1:20,000 (Sigma-Aldrich, St. Louis,MO)]were
used to detect labeled proteins, with enhanced chem-
iluminescence (GE Healthcare, Little Chalfont, UK). Mem-
branes were reblotted for ß-actin [mouse, dilution 1:4000
(Abcam, Cambridge, UK)] as a loading control. Intensity for
Dlp1 in mitochondrial extracts was measured using Quantity
One (Biorad). Each value was normalized to the average in-
tensity of Dlp1 from control patients.
Tissue Staining
Fixed and parafﬁn-embedded tissue sections were deparafﬁ-
nized by washing 4 for 10 minutes in xylene and 2 for 5The American Journal of Pathology - ajp.amjpathol.orgminutes in 50% xylene/50% ethanol. Tissue was rehydrated
by washing 2 for 5 minutes in 100% ethanol, 3 for 1
minute in 95%, 70%, and 50% ethanol, rinsed in deionized
water, and washed 2 for 5 minutes in phosphate-buffered
saline (PBS). Tissue was heated (100C) in 10 mmol/L
citric acid (pH 6.0) for 15 minutes, cooled for 30 minutes at
room temperature (25C), andwashed 3 for 10minutes with
TBS-T. Tissue was blocked overnight in 5% normal goat
serum (NGS), 2% BSA, and 0.25% Triton X-100, made in
TBS-T. Tissue was incubated with primary antibodies in
blocking solution overnight [rabbit anti-tyrosine hydroxylase,
dilution 1:500 (Pel-Freez Biologicals, Rogers, AR), mouse
anti-Dlp1, dilution 1:100 (BD Biosciences), rabbit antie
mitogen-activated protein (MAP) 2, dilution 1:200 (Milli-
pore), and rabbit anti-glial ﬁbrillary acidic protein (GFAP),
dilution 1:500 (Dako, Golstrup, Denmark)]. After incubation
with primary antibodies, tissue was washed with 5%NGS and
2% BSA in TBS-T 3 for 10 minutes, and incubated with
secondary antibodies conjugated with Alexa Fluor 488 or 568
(dilution 1:500; Life Technologies, Carlsbad, CA) in 5%NGS
and 2% BSA, made in TBS-T, overnight. After incubation
with secondary antibodies, tissue was washed 3 for 10 mi-
nutes in TBS-T, followed by rocking in 0.3% Sudan Black in
70% ethanol for 30 minutes. Tissue was rinsed twice in 70%
ethanol, washed 3 for 10 minutes in TBS-T, and mounted
with Vectashield with DAPI (Vector Laboratories, Burlin-
game, CA).
Fluorescence Staining
Cells were ﬁxed in 4% paraformaldehyde for 30 minutes at
room temperature, washed 2 for 5 minutes with PBS, and
blocked in 4% NGS, 1% BSA, and 0.4% Triton X-100 for 1
hour at room temperature. Primary antibodies were diluted
in blocking buffer and incubated overnight at 4C . Co-
cultured cells were incubated with rabbit anti-tyrosine hy-
droxylase (TH; dilution 1:200; Millipore) and mouse anti-
MAP2 (dilution 1:200; Abcam). Astrocytes transfected with
488-tagged siRNA were incubated with mouse antieGLT-1
[dilution 1:200; a kind gift from Dr. Jeffry Rothstein (Johns
Hopkins Medical School, Baltimore, MD)] or rabbit anti-
EAAT1 (dilution 1:200; Abcam), each with chicken anti-
GFAP (dilution 1:500; Millipore). Astrocytes ﬁxed after
mitochondrial imaging were stained with rabbit anti-GFAP.
Cells were washed 3 for 5 minutes with 0.1% Tween-20 in
PBS and incubated with secondary antibodies conjugated
with Alexa Fluor 488, 568, or 633 diluted 1:500 (488 and
568) or 1:100 (633) in 0.3% Triton X-100 in PBS for 1 hour
at room temperature, followed by washing 3 for 5 minutes
with 0.1% Tween-20 in PBS. Stained cells were mounted
with Vectashield with DAPI.
Astrocyte and Astrocyte/Neuron Cultures
Animal use was approved by the Institutional Animal Care
and Use Committee of the University of Washington537
Hoekstra et al(Seattle, WA). Primary cortical astrocytes were prepared
from postnatal day 0 to 1 Sprague-Dawley rats. Cortices were
isolated and cleaned of blood vessels and meninges in cold
dissecting media (Dulbecco’s modiﬁed Eagle’s medium F12;
LifeTechnologies). Tissuewas digested for 30minutes at 37C
in Dulbecco’s modiﬁed Eagle’s medium F12 with 0.5 mmol/L
EDTA, 0.2 mg/mL L-cysteine, 15 U/mL papain (Worthington
Biochemical, Lakewood, NJ), and 10 mg/mL DNase
(Worthington Biochemical) (10-mL digestion media per three
brains). After digestion, cortical tissue was washed three times
with culture media [Dulbecco’s modiﬁed Eagle’s medium F12
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin (Corning, Tewksbury, MA)]. After washing,
corticeswere trituratedwith aﬁre-polishedPasteur pipette in10
mL of culture media. Tissue was allowed to settle, and the
supernatant was passed through a cell strainer (pore size,
100 mm). The remaining tissue was triturated again in 5 mL of
culturemedia, passed through a strainer, and combinedwith the
previous 10 mL of triturated cells. The resulting cells were
seeded in culture media, into vented 75-cm2 ﬂasks coated with
poly-D-lysine, two brains per ﬂask. Culture medium was
changed 24 hours later, and astrocytes were maintained at
37C, 5%CO2, until they reached conﬂuence (9 to 10 days), at
which point they were plated for use.
Flasks containing conﬂuent astrocyte cultures were gently
shaken to remove microglia, washed once with PBS, and
incubatedwith0.25% trypsinEDTAat37Cfor approximately
5 minutes. Cells were washed with an equal volume of media,
collected into a 50-mL conical tube, and centrifuged at
1900 g for 10 minutes at room temperature. The resulting
pellet was resuspended to a ﬁnal volume of 10 mL per ﬂask
collected, and counted using a hemocytometer. Cells were
plated onto glass coverslips (for co-culture, 25  104 cells
per coverslip) or into 6-well plates (for Western blot anal-
ysis, 10  105 cells per well). Cultures were at least 95%
GFAP positive.
Astrocytes were transfected with Lipofectamine 2000 (Life
Technologies), according to the manufacturer’s instructions,
with slight modiﬁcations. Control or Dlp1 siRNA (Qiagen,
Venlo, the Netherlands), 2 pmol per well for 24-well plates or
200 pmol per well for 6-well plates, was used. Astrocytes were
maintained in media and collected at times similar to when
media changes and glutamate treatment occurred for co-
cultures, respectively (described later). Similar plating and
transfection with 488-tagged siRNA was performed on astro-
cytes to assess GLT-1 and GLAST localization. Transfection
efﬁciency differed depending on the technique for which it was
used.Whenplated onto glass coverslips (as in astrocyte-neuron
co-cultures) or for Western blot analysis, transfection with
siRNA efﬁciency was between 60% and 70%, assessed using
Western blot analysis for Dlp1.When plated for Ca2þ imaging
(35-mm glass-bottom dishes, same volumes as 6-well plates),
efﬁciency was approximately 95%, assessed by imaging
488-tagged siRNA after transfection (Dlp1 knockdown by
488-tagged siRNA was validated with Western blot analysis).
When plated for mitochondrial imaging (described later),538efﬁciencywas<50%, assessed by imaging 488-tagged siRNA
after transection; however, staining for MnSOD, to observe
mitochondrial morphological characteristics, in plates trans-
fected similarly to those for Ca2þ imaging, showed the same
morphological phenotype after Dlp1 knockdown.
To prepare co-cultures, timed pregnant Sprague-Dawley rats
(Harlan Animal Research Labs, Indianapolis, IN) were anes-
thetized with carbon dioxide. Pups (embryonic days 16 to 18)
were removed, and the brains were placed in cold neuronal
dissection media [Neurobasal A supplemented with B27 and
0.5 mmol/L L-glutamine (Life Technologies)]. Ventral mes-
encephalons were dissected from the brains and digested for 15
minutes at 30C in 12 mL Hibernate A without calcium chlo-
ride (BrainBits, Springﬁeld, IL), 0.5 mmol/L L-glutamine, 15
U/mL papain, and 17 mg/mL DNase. Tissue was washed three
times with neuronal dissection media and triturated in 2 mL of
the same media with a ﬁre-polished Pasteur pipette. Tissue was
allowed to settle, and the supernatant was passed through a cell
strainer (pore size, 100 mm). Trituration and cell straining were
repeated twice more. Cells were spun at 200 g for 5 minutes
at room temperature. The resulting pellet was resuspended in
neuronal media (Neurobasal A supplemented with B27, 2
mmol/L L-glutamine, and 1% penicillin/streptomycin) and
counted using a hemocytometer. Cells (12.5  104 per well)
were plated onto transfected astrocytes in neuronal media.
Neurons were allowed to grow for 8 days before treatment.
Live and Immunoﬂuorescence Imaging
To quantify Dlp1 in tissue, Z-series images were captured
for 15 randomly selected ﬁelds of GFAP-positive astrocytes
and 20 ﬁelds of MAP2-positive (and neuromelanin negative
for SNpc) or TH-positive neurons in each region. A single
image from the middle section was selected to quantify
Dlp1 intensity. Astrocytes in the SNpc were imaged at
magniﬁcation 100 using a Biorad LS2000 laser-scanning
confocal microscope. All other imaging was done at 60
magniﬁcation using a Nikon Eclipse Ti microscope (Nikon
Instruments Inc., Melville, NY). Microscope settings were
kept the same for each cell type from each region using NIS-
Elements software version 3.2 (Nikon Instruments Inc.). For
quantiﬁcation, each value was normalized to the average
Dlp1 intensity of the control patients for the cell type and
region being analyzed. All image analysis was performed
using ImageJ software version 10.2 (NIH, Bethesda, MD)
and NIS-Elements software. Images were deconvolved, and
Dlp1 intensity was measured by manually tracing cells,
selecting a region of interest, and calculating the mean
ﬂuorescence of the region. Image capture and quantiﬁcation
were done without knowledge of case diagnosis.
Astrocytes used for intracellular or mitochondrial Ca2þ im-
aging were plated onto 35-mm dishes with a 14-mm glass
coverslip (MatTek, Ashland, MA), coated with poly-D-lysine.
Cells (25  104 per well) were plated onto the coverslips at a
ﬁnal volume of 500 mL, and returned to 37C for 2 hours to
allowcells to adhere.After 2 hours,mediumwas added to aﬁnalajp.amjpathol.org - The American Journal of Pathology
Figure 1 Dynamin-like protein 1 (Dlp1) expression is decreased in the
substantia nigra pars compacta (SNpc) of Parkinson disease (PD) patients.
Western blot analysis (A) and densitometry (C) of the mitochondrial-
enriched fraction of the SNpc from control patients (N Z 4) and PD
patients (NZ 4) show decreased Dlp1 in mitochondria-enriched tissue (the
units for molecular weight markers on the right of the Western blot are kDa).
B: Fluorescent staining of Dlp1 (green) and glial ﬁbrillary acidic protein
(GFAP; red) in the SNpc of control patients and PD patients. Arrows point at
Dlp1 and GFAP colocalization. D: Quantiﬁcation of Dlp1 intensity in astro-
cytes from the SNpc of control (NZ 6 cases, 109 cells) and PD patients (NZ
6 cases, 118 cells). Data are presented as means  SEM. *P < 0.05, ***P <
0.001 by two-sided unpaired t-test. Scale barZ 20 mm (B).
Astrocytic Mitochondrial Dynamics in PDvolume of 2 mL. Astrocytes were transfected as with 6-well
plates. For transfection of Mito-DsRed2 plasmid (Clontech,
Mountain View, CA) and 488-tagged siRNA, 6-well plasmid
instructions were followed using 4 mg plasmid and 100 pmol
siRNA per plate.
To measure astrocyte intracellular or mitochondrial Ca2þ
responses to glutamate, cells were loaded with Oregon
Green 488 1,2-bis (aminophenoxy) ethane-N,N,N0,N0-
tetraacetic acid acetoxymethyl ester or rhod-2 AM, respec-
tively (Life Technologies). The dye (50 mg) was shaken in
10 mL of 15% Pluronic F-127 in dimethyl sulfoxide (Life
Technologies) at 4C for 30 minutes. Dye was diluted to a
ﬁnal concentration of 4 mmol/L in neuronal media and
incubated with the cells for 30 minutes at 37C (Oregon
Green) or room temperature (rhod-2 AM). Cells were then
either washed 3 for 10 minutes with neuronal media and
imaged for total intracellular Ca2þ after the third wash or
washed 3 with neuronal media and incubated at 37C for 1
hour before imaging for mitochondrial Ca2þ.
All Ca2þ imaging was performed using a Nikon Eclipse Ti
microscope andNIS-Elements Software at60magniﬁcation
and 37C. Fields of cells were randomly selected, and ﬂuo-
rescent intensity was measured every 200 milliseconds (total
intracellular Ca2þ) or 1 second (mitochondrial Ca2þ). Cells
were imaged for 2 minutes, at which point glutamate was
added to a ﬁnal concentration of 100 mmol/L, and responses
were recorded for approximately 8 minutes after stimulation.
Three to four plates were used per replicate. Response data
were exported to Microsoft Excel (Redmond, WA) and
quantiﬁed. Intracellular Ca2þ responses were categorized as
response types. Types 1 and 2 were deﬁned by large increases
of intracellular Ca2þ. Type 1 responses lasted >60 seconds,
and type 2 responses were 60 seconds or less. Types 3 and 4
were deﬁned as having Ca2þ oscillations, with type 3 having
lower frequency (<0.19 Hz) and type 4 having greater fre-
quency (at least 0.19 Hz). Proportions of responses were
calculated for each replicate. Mitochondrial Ca2þ responses
were calculated bymeasuring the change in ﬂuorescence from
baseline and dividing by baseline ﬂuorescence. Values for
each cell were calculated and used for analysis.
Mitochondrial Measurements
To assess mitochondrial movement, astrocytes were main-
tained in medium identical to that used for astrocyte/neuron
co-cultures. Three random ﬁelds of astrocytes positive for
the siRNA (green) and Mito-DsRed2 plasmid were selected
for each plate in each replicate and imaged at 37C. Images
were captured every 5 seconds for 5 minutes. Movement
was assessed by measuring the net distance moved by
mitochondria within the processes toward (retrograde) or
away (anterograde) from the astrocyte cell body during the
5-minute span. Measurements for mitochondria movement
in each direction were averaged for each cell.
After imaging, astrocytes were ﬁxed and stained with
GFAP to assess mitochondrial length and morphologicalThe American Journal of Pathology - ajp.amjpathol.orgcharacteristics. Ten random ﬁelds were selected, and Z-series
images were captured. Files were deconvolved, and
maximum intensity projections were generated. Mitochondria
within the processes were analyzed because individual
mitochondria were more easily resolved than those in the cell
body. For astrocytes with Dlp1 knocked down, it was not
uncommon for elongated mitochondria to continue into the
cell body. In this event, the process was cropped at the cell
body and mitochondria were analyzed as if the point where
they reached the cell body was the end. The perimeters of
mitochondria were selected using the software and, from this,
length and area were automatically calculated. To assess
density, the number of mitochondria in the process was539
Hoekstra et alcounted and divided by the area of the process. For each
measurement, the values for individual cells were averaged.
Glutamate Treatment of Astrocyte-Neuron Co-Cultures
To assess astrocyte protection against excitotoxic environ-
ments, co-cultures were gently shaken to remove residual
microglia and treated with normal neuronal media (No
Treatment), neuronal media supplemented with 10 mmol/L
glutamate (10 mmol/L Glu), or neuronal media supplemented
with 10 mmol/L each of glutamate and MK-801 (10 mmol/L
Glu þ MK-801; Sigma) for 10 minutes. Treatments were
replaced with normal neuronal media and allowed to recover
for 1 hour, at which point co-cultures were ﬁxed and stained.
H3-D-Aspartate Uptake
Uptake assays were performed on co-cultures in duplicate,
similar to published protocols.21 Cells were washed twice
with warm Krebs-Ringer solution (16 mmol/L sodium
phosphate, 119 mmol/L NaCl, 4.7 mmol/L KCl, 1.8
mmol/L CaCl2, 1.2 mmol/L MgSO4, 1.3 mmol/L EDTA,
and 5.6 mmol/L glucose; pH 7.4). After the second wash,
cells were incubated with Krebs-Ringer solution with H3-
D-aspartate (1.3 mmol/L; 0.03 mCi/mL, speciﬁc activity 1
mCi/mL; American Radiolabeled Chemicals, St. Louis,
MO) at 37C for 10 minutes. Co-cultures were washed three
times with ice-cold Krebs-Ringer solution. After the third
wash, cells were rocked in 1N NaOH for 30 minutes at roomFigure 2 Dynamin-like protein 1 (Dlp1) expression is decreased in neurons
patients. A: Fluorescent staining of Dlp1 (green) and tyrosine hydroxylase (TH; red
in dopaminergic (DAergic) neurons from SNpc of control (Ctrl; NZ 6 cases, 253 ce
and mitogen-activated protein (MAP) 2 (red) without neuromelanin in SNpc of c
neurons from control (N Z 6 cases, 185 cells) and PD patients (N Z 6 cases,
sided unpaired t-test. Scale bar Z 20 mm (A and C).
540temperature. The resulting solutions were collected in
scintillation ﬂuid and measured using a scintillation counter.
For each replicate, H3 measurements were averaged for each
group (siRNA) and normalized to the value for co-cultures
where control siRNA was transfected into astrocytes.
Measurement of Neurons
A Nikon Eclipse 80i microscope (Nikon Instruments Inc.)
was used to capture images for assessing viability of neurons
in response to treatments. Ten random ﬁelds of TH-positive
neurons and their processes were captured and traced using
Neurolucida (MBF Bioscience, Williston, VT) to assess
average process (neurite) length and number of branch
points. To assess the viability of non-dopaminergic (non-
DAergic) neurons in response to treatments, ﬁve random
ﬁelds of MAP2-positive and TH-negative neurons were
captured and similarly traced. Cells from each replicate were
normalized to the average length or number of branch points
of neurons from No Treatment control siRNA co-cultures.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
version 6 (San Diego, CA). Differences between groups
were assessed using two-sided unpaired t-tests, two-way
analysis of variance with Bonferroni correction, or two-
sample Kolmogorov-Smirnov test to assess if the groups
were equal, and are speciﬁed in each ﬁgure legend.in the substantia nigra pars compacta (SNpc) of Parkinson disease (PD)
) in the SNpc of control and PD patients. B: Quantiﬁcation of Dlp1 intensity
lls) and PD patients (NZ 6 cases, 143 cells). C: Fluorescent staining of Dlp1
ontrol and PD patients. D: Quantiﬁcation of Dlp1 intensity in non-DAergic
175 cells). Data are presented as means  SEM. ***P < 0.001 by two-
ajp.amjpathol.org - The American Journal of Pathology
Table 1 Clinical Data for PD and Control Cases Used for SNpc and
Frontal Cortex Cases




1 Ctrl SNpc 55 M 9:30
2 Ctrl SNpc 70 F 6:00
3 Ctrl SNpc 79 M 7:50
4 Ctrl SNpc 78 M 4:00
5 Ctrl SNpc 79 F 2:30
6 Ctrl SNpc 81 M 7:30
7 PD SNpc 57 M 17:45
8 PD SNpc 82 F 11:00
9 PD SNpc 81 M 6:30
10 PD SNpc 80 M 6:30
11 PD SNpc 58 F >24
12 PD SNpc 73 M 3:50
13 Ctrl FC 78 M 4:00
14 Ctrl FC 78 M 6:00
15 Ctrl FC 81 M 5:30
16 Ctrl FC 81 M 6:00
17 Ctrl FC 82 F 3:30
18 Ctrl FC 91 F 11:00
19 PD FC 73 M 3:50
20 PD FC 78 M 5:00
21 PD FC 81 M 6:30
22 PD FC 82 F 11:00
23 PD FC 91 F 4:10
24 PD FC 89 F <12
All cases were devoid of cortical neuroﬁbrillary tangles.
F, female; M, male; Ctrl, control patient; FC, frontal cortex; PD, Parkinson
disease; PMI, post-mortem interval; SNpc, substantia nigra pars compacta.
Astrocytic Mitochondrial Dynamics in PDSigniﬁcance was deﬁned as P < 0.05. All bar graphs are
presented as means  SEM.
Results
Dlp1 Expression Decreases in Astrocytes and Neurons
from PD Patients
Previously, by using mass spectrometry and pooled SNpc
samples, we found that PD patients had lower Dlp1 expression
compared to healthy controls.14 Our goal was to demonstrate
the previous ﬁndings in individual PD cases with a different
technology. Therefore, the SNpc mitochondrial fraction from
four PD and four control patients was examined via Western
blot analysis with an anti-Dlp1 antibody. In agreement with
our previous work,14 Dlp1 protein expression was signiﬁ-
cantly lower in PD patients (Figure 1, A and C).
The astrocytic Dlp1 expression levels were measured in
the SNpc of PD and control patients by immunoﬂuorescence.
We found an obvious decrease of astrocytic Dlp1 expression
in PD patients (Figure 1, B and D). In addition, neuronal
Dlp1 expression was measured in DAergic (Figure 2, A and
B; information for human tissue is in Table 1) and non-
DAergic neurons in the SNpc of PD patients and controls
in Figure 2, C and D. Again, Dlp1 immunoﬂuorescence was
signiﬁcantly decreased in both DAergic and non-DAergic
neurons (Figure 2, AeD). Next, we asked whether the
observed decrease in Dlp1 expression also occurred in his-
tologically normal cortex from PD patients (ie, PD patients at
a relatively early stage, without apparent cortical neuro-
degeneration). Remarkably, Dlp1 expression was decreased
in both cell types (Figure 3, AeD).
Dlp1 Affects Astrocytic Mitochondrial Morphological
Characteristics and Localization
To understand the biological effects of decreased Dlp1
expression in astrocytes, we performed Dlp1 (Dnm1l)
knockdown by siRNA in primary cortical rat astrocytes
(Figure 4B). No change was observed in expression levels
of other mitochondrial ﬁssion/fusion proteins (optic
atrophy 1, mitofusins 1 and 2, and ﬁssion 1) assessed by
Western blot analysis (data not shown). Astrocytes
cotransfected with 488-tagged siRNA and a Mito-DsRed2
plasmid, to observe mitochondria, were stained for GFAP.
Knockdown of Dlp1 in astrocytes resulted in dramatic
morphological changes primarily characterized by an elon-
gated, fused mitochondrial network (Figure 4A), similar to
what has been observed in other cell types.12,22 Mitochon-
dria located in astrocyte processes had clear morphological
features and, therefore, were used to quantitatively compare
morphological and localization differences after Dlp1
knockdown. Mitochondria in astrocytes transfected with
Dlp1 siRNA were signiﬁcantly longer than those in astro-
cytes transfected with non-speciﬁc (control) siRNA
(Figure 4, A and B). In addition, the area and perimeter ofThe American Journal of Pathology - ajp.amjpathol.orgmitochondria were signiﬁcantly larger in astrocytes after
Dlp1 knockdown (Figure 4, A, C, and D). Furthermore,
there were fewer mitochondria within astrocyte processes
after Dlp1 knockdown (Figure 4E), indicating that knock-
down of Dlp1 resulted in extensive fusion of mitochondria.
Live cell imaging was used to measure net anterograde and
retrograde mitochondrial movement to determine whether
Dlp1 knockdown altered mitochondrial motility
(Figure 5A). The net distance traveled by mitochondria, in
each direction, was greater in astrocytes transfected with
control siRNA compared to astrocytes transfected with Dlp1
siRNA (Figure 5, B and C, and Supplemental Movies S1
and S2). This evidence suggests that Dlp1 plays a signiﬁ-
cant role in astrocytic regulation of the morphological fea-
tures, localization, and motility of their mitochondria.Astrocytic Dlp1 Protects Neurons from Excessive
Glutamate
A co-culture system of rat astrocytes (with or without Dlp1
siRNA) and neurons from the ventral mesencephalon was
used to determine whether decreased astrocytic Dlp1 im-
pairs astrocytic protection of neurons from the excitotoxic
effects of excess glutamate. When DAergic neurons were541
Figure 3 Dynamin-like protein 1 (Dlp1) expression is decreased in neurons and astrocytes in the frontal cortex of Parkinson disease (PD) patients. A:
Fluorescent staining of Dlp1 (green) and mitogen-activated protein (MAP) 2 (red) in frontal cortex of control and PD patients. B: Quantiﬁcation of Dlp1
intensity in neurons from control (NZ 6 cases, 357 cells) and PD patients (NZ 6 cases, 385 cells). C: Fluorescent staining of Dlp1 and glial ﬁbrillary acidic
protein (GFAP; red) in frontal cortex from control and PD patients. Arrows point at Dlp1 and GFAP colocalization. D: Quantiﬁcation of Dlp1 intensity in
astrocytes from control (NZ 6 cases, 230 cells) and PD patients (NZ 6 cases, 229 cells). Data are presented as means  SEM. ***P < 0.001 by two-sided
unpaired t-test. Scale bar Z 20 mm (A and C). Ctx, cortex.
Hoekstra et alco-cultured with astrocytes transfected with control siRNA,
10 mmol/L glutamate did not affect DAergic neurite length
or the number of branch points (highlighted by TH-positive)
(Figure 6, AeC). Conversely, when DAergic neurons were
co-cultured with astrocytes transfected with Dlp1 siRNA
(decreased Dlp1 expression), the addition of 10 mmol/L
glutamate decreased DAergic neurite length and the number
of branch points. The administration of the NMDA receptor
antagonist, MK-801, at the time of glutamate treatment pre-
vented these morphological changes (Figure 6, AeC). This
evidence indicates that astrocytic Dlp1 promotes the pro-
tection of DAergic neurons from glutamate excitotoxicity.
Similar measurements were performed on non-DAergic
MAP2-positive neurons to assess if this effect was speciﬁc to
TH-positive neurons. As was the case with TH-positive neu-
rons, treatment with 10mmol/L glutamate did not affect neurite
length or branch point number of non-DAergic neurons in co-
culture with astrocytes transfected with control siRNA
(Figure 6, BeD). However, in non-DAergic neurons co-
cultured with astrocytes transfected with Dlp1 siRNA, the
addition of 10 mmol/L of glutamate resulted in decreased
neurite length and branch point number. Again, this effect
could be prevented by the addition of MK-801 (Figure 6,
BeD). These observations suggest that decreased astrocytic
Dlp1 expression impairs their ability to protect neighboring
neurons from the harmful effects of excess glutamate. Astro-
cytic neuronal protection should be dependent on proper
function of the glutamate transport system. Therefore, we
assessed the uptake of H3-D-aspartate to investigate whether
the loss of astrocytic Dlp1 impaired the glutamate transport542system. The cultures with astrocytes transfected with Dlp1
siRNA absorbed less H3-D-aspartate than cultures with astro-
cytes treated with control siRNA (Figure 6E). This result
supports the hypothesis that astrocytic glutamate transport is
impaired by decreased Dlp1 expression.
Because Dlp1 is reported to interact with GLT-1,15 we
investigated whether decreased Dlp1 expression alters the
expression and/or localization of GLT-1. Western blot analysis
of astrocytic GLT-1 showed no change in protein expression
when transfected with Dlp1 siRNA (Supplemental
Figure S1A). We immunoﬂuorescently stained GLT-1 in
astrocytes transfected with Dlp1 siRNA to observe astro-
cytic GLT-1 localization. Again, the localization of GLT-1
did not appear to be affected by Dlp1 expression
(Supplemental Figure S1B). In similar experiments, we
examined the other major astrocytic glutamate transporter,
GLAST. Similarly, Dlp1 siRNA did not interfere with
GLAST expression or localization (Supplemental
Figure S1, C and D). Therefore, given that protein knock-
down in these experiments was comparable to those from
the co-culture experiments (approximately 60% to 70%),
alterations to the glutamate transport system caused by
astrocytic Dlp1 knockdown did not occur through changes
in the expression or localization of the major astrocytic
glutamate transporters.
Dlp1 Affects Astrocytic Regulation of Calcium Entry
Cultured astrocytes were imaged in the presence of the
Ca2þ-sensitive dye Oregon Green 1,2-bis (aminophenoxy)ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Knockdown of dynamin-like protein 1 (Dlp1; DNM1L) in astrocytes results in elongation and interconnection of mitochondria. A: Representative images
of rat astrocytes transfected with non-speciﬁc [control (ctrl)] siRNA or siRNA targeting Dlp1, each labeled with a 488 tag, and a Mito-DsRed2 plasmid to observe
mitochondria. Cells that were positively transfected with both siRNA and Mito-DsRed2 were identiﬁed by the presence of green and red ﬂuorescence. Western blot
analysis (inset, B) conﬁrmed siRNA decreased Dlp1 expression. Length (B), area (C), perimeter (D), and density (E) of mitochondria from processes of transfected
astrocytes (N Z 5 replicates; 50 to 56 cells per group). Data are presented as means  SEM. ***P < 0.001 by two-sided unpaired t-test.
Astrocytic Mitochondrial Dynamics in PDethane-N,N,N0,N0-tetraacetic acid to determine whether
decreased Dlp1 alters astrocytic intracellular Ca2þ re-
sponses to extracellular glutamate. Astrocyte responses to
glutamate could be categorized into four general categories.
Under control conditions, a minority of cells responded with a
single, large increase in intracellular Ca2þ, which could be
either prolonged (taking >60 seconds to return to baseline) or
attenuated (taking 60 seconds or less to return to baseline). We
categorized these cell responses as types 1 and 2, respectivelyThe American Journal of Pathology - ajp.amjpathol.org(Figure 7A). The remaining cells responded with intracellular
Ca2þ oscillations, and we categorized these cell responses by
oscillation frequency. Type 3 responses were characterized by
less frequent oscillations (<0.19 Hz), and type 4 responses
were characterized by more frequent oscillations (0.19 Hz)
(Figure 7A). Control astrocytes demonstrated mostly type 3
and 4 responses, whereas astrocytes with decreased Dlp1 had
fewer type 3 and 4 responses and signiﬁcantly more type 1
responses (Figure 7B). These results indicate that astrocytic543
Figure 5 Knockdown of dynamin-like protein 1 (Dlp1; DNM1L) in as-
trocytes decreases mitochondrial movement. A: Representative image for
measurements of distance for astrocytes transfected with control (ctrl) or
Dlp1 siRNA. Arrows on the top panels mark beginning position, and arrows
on the bottom panels mark ending position. B: Net movement for mito-
chondria away from the cell body. C: Net movement for mitochondria to-
ward the cell body (N Z 6 replicates; 28 cells per group). Data are
presented as means  SEM. *P < 0.05, **P < 0.01 by two-sided unpaired
t-test. Scale bar Z 1 mm (A).
Hoekstra et alDlp1 knockdown results in elevated intracellular Ca2þ in
response to glutamate.
Astrocyte responses to glutamate are initiated by an
intracellular release of Ca2þ from the endoplasmic reticulum
(ER), which precedes Ca2þ-induced Ca2þ entry from the
extracellular space in a process referred to as store-operated
calcium entry.23 In addition, the binding of glutamate to
ionotropic receptors allows Ca2þ inﬂux from the extracellular
space.23 Therefore, the Ca2þ response could be driven by
intracellular and/or extracellular Ca2þ in astrocytes with
decreased Dlp1 expression. To determine how extracellular
Ca2þ contributes to the four previously mentioned calcium
responses, glutamate-induced Ca2þ responses were observed
in the presence of the calcium chelator, EGTA. When as-
trocytes were bathed with 2 mmol/L EGTA, no type 1 re-
sponses were observed (Figure 7B). This result suggests that
extracellular Ca2þ is necessary for the extended Ca2þ entry
observed in type 1 responses. However, the pattern of Ca2þ
waves was not different between astrocytes transfected with
control or Dlp1 siRNA.
Decreased Dlp1 Impairs Mitochondrial Buffering of
Extracellular Ca2þ
It is well-known that mitochondria buffer intracellular
Ca2þ.24 Given that the morphological characteristics and
distribution of mitochondria are altered in astrocytes after
Dlp1 knockdown, the Ca2þ buffering capacity of mito-
chondria could be limited when challenged with increased
extracellular glutamate. Rhod-2 AM, a ﬂuorometric dye
sensitive to mitochondrial Ca2þ, was used to assess the
mitochondrial buffering capacity of astrocytes transfected
with control or Dlp1 siRNA in response to glutamate. Dlp1544siRNA-transfected astrocytes had lower mitochondrial peak
Ca2þ amplitudes than those of control siRNA-transfected
astrocytes (Figure 8, A and B). Therefore, knockdown of
astrocytic Dlp1 impairs mitochondrial Ca2þ buffering in
response to glutamate. In addition, the differences observed
in cellular Ca2þ responses to glutamate were mediated by
the regulation of extracellular Ca2þ. Therefore, mitochon-
drial buffering of glutamate-induced extracellular Ca2þ
entry potentially plays a fundamental role in regulating
overall cellular Ca2þ responses.Discussion
Herein, we investigated the role of Dlp1 in PD pathogenesis.
Dlp1 was lower in the mitochondrial fractions from the
SNpc of PD patients, which was in agreement with our
previous results.14 In addition, Dlp1 was decreased in as-
trocytes and neurons from the SNpc of PD patients. A
decrease in Dlp1 has been described in hippocampal neu-
rons from patients with Alzheimer disease.22 The current
investigation is the ﬁrst study to demonstrate decreased
Dlp1 in astrocytes from PD patients. Our ﬁnding that Dlp1
is decreased in astrocytes and neurons in the frontal cortices
of PD patients is also signiﬁcant. Cortical regions likely play
a role in the nonmotor symptoms of PD, including depres-
sion and impaired cognitive functions,2,3 some of which
occur before the onset of motor symptoms. The cortical
samples examined in our study were obtained from patients
without obvious cortical neurodegeneration or Lewy body
disease, which occurs in late stages of PD. Therefore,
decreased Dlp1 expression may represent an early event in
PD neurodegeneration.
The second important ﬁnding is that decreased Dlp1 has
dramatic effects on the morphological characteristics of
astrocytic mitochondria. Astrocytes constitute a large pro-
portion of cells in most brain regions, including the
SNpc,25,26 and they perform a variety of protective functions
that promote neuronal survival. Decreased astrocytic Dlp1 in
our in vitro system altered mitochondrial morphological
characteristics and localization. Furthermore, Dlp1 knock-
down signiﬁcantly increased mitochondrial length, perimeter,
and area and decreased the density of mitochondria within
astrocyte processes. These results are consistent with pub-
lished studies, which show alterations in mitochondrial dy-
namics in PD that may act through Dlp1.12,13 Finally, Dlp1
knockdown hinders anterograde and retrograde mitochondrial
movements, which leads to their abnormal localization. Thus,
the astrocytic capacity for maintaining the neuronal envi-
ronment may be diminished by suboptimal positioning of
their mitochondria27,28 (discussed later).
As previously mentioned, it has become increasingly
recognized that astrocytes play a critical role in neuronal sur-
vival,7 and the mechanisms by which astrocytes contribute to
disease are a major area of interest. Changes in PD-related
proteins in astrocytes of PD patients have implicated astrocyteajp.amjpathol.org - The American Journal of Pathology
Figure 6 Astrocytic dynamin-like protein 1 (Dlp1) decreases the ability of astrocytes to protect neurons against the effects of excess glutamate. A:
Representative images of dopaminergic (DAergic) neurons, indicated by tyrosine hydroxylase (TH) staining, co-cultured with astrocytes transfected with
control (ctrl) or Dlp1 siRNA and treated as indicated. Neurons cultured with Dlp1-transfected astrocytes show shorter processes and fewer branch points after
glutamate treatment. B: Representative images of non-DAergic neurons, indicated by mitogen-activated protein (MAP) 2 staining, cultured with astrocytes
transfected and treated similar to A. C: Average neurite length for images in A and B (n Z 3 replicates, 72 to 101 cells per group for TH-positive and
approximately 650 to 800 cells per group for MAP2). D: Average number of branch points for images in A and B (nZ 3 replicates). Neurite lengths and number
of branch points were normalized to the average value for the No Treatment ctrl siRNA group for each replicate, and each value was used for analysis. E:
Aspartate uptake decreases in cultures similar to A and D when astrocyte Dlp1 decreases. Data are presented as means  SEM. **P < 0.01, ***P < 0.001 by
two-way analysis of variance with Bonferroni correction (C and D); ***P < 0.001 by two-sided unpaired t-test (E).
Astrocytic Mitochondrial Dynamics in PDdysfunctionas a contributing factor in diseasepathogenesis.29,30
Animalmodels ofPDsupport this concept and suggest impaired
astrocyte glutamate regulation as a potential mechanism.19,31
Our study links pathologically relevant changes in astrocytic
protein expression to neuronal damage due to deﬁciencies in the
glutamate transport system. The loss of Dlp1 impairs astrocyte-
mediated neuroprotection against the damaging effects of
glutamate, which occur via excessive signaling through
NMDA receptors on neurons. Such effects were not speciﬁc to
DAergic neurons, which suggests that excitotoxicity is not the
primary mechanism of speciﬁc DAergic neuronal death in PD.
Gradual loss of DAergic neurons is a classic neuropathological
feature found in PD. DAergic neurons from the SNpc may,
therefore, be selectively vulnerable to a lifetime of small, but
cumulative, excitotoxic insults or rapidly vulnerable to a large
excitotoxic insult. This concept is partially supported by the
ﬁnding that methylphenylpyridium ionepositive toxicity,
which targets DAergic neurons, is enhanced by the application
of glutamate.32 In addition, when studied using in vivo toxicant-
based models of PD, DAergic neuron death largely results
from excessive reactive oxygen species (ROS) production and/
or the inhibition of mitochondrial function. That such modelsThe American Journal of Pathology - ajp.amjpathol.orgcan be rescued by the administration of glutamate receptor an-
tagonists19,20 implies that excitotoxicity plays a contributing,
rather than primary, role in PDandmay exacerbate the effects of
another insult.
Finally, we studied the mechanism by which impaired
astrocytic mitochondrial dynamics affect the glutamate
transport system. We initially tested the hypothesis that
impaired glutamate transport and the ensuing increased
sensitivity of neurons to glutamate-mediated excitotoxicity
in the presence of astrocytes with decreased Dlp1 expres-
sion resulted from altered expression or localization of
astrocytic glutamate transporters, particularly GLT-1, due to
separate reports that indicated Dlp1 may compartmentalize
mitochondria with GLT-1.15 Knockdown of astrocytic Dlp1
did not appear to affect expression or localization of either
GLT-1 or GLAST, indicating alterations in glutamate
handling occurred through a separate mechanism(s).
Glutamate-induced Ca2þ responses were, therefore, used to
assess the effects of Dlp1 knockdown on glutamate
handling, because Ca2þ is critically important for astrocyte
function, including glutamate clearance.33,34 Indeed, astro-
cytic Dlp1 knockdown led to increased, prolonged Ca2þ545
Figure 7 Intracellular Ca2þ is increased in response to glutamate when
astrocytic Dlp1 is knocked down. A: Representative images of the four
primary astrocyte Ca2þ responses to glutamate. Traces represent intracel-
lular Ca2þ signals from astrocytes treated with glutamate (black line above
trace). For types 1 and 2, the Y scale bar represents 500 ﬂuorescent units
(FUs) and the X scale bar represents 25 seconds. For type 3, the Y scale bar
represents 50 FUs and the X scale bar represents 25 seconds. For type 4, the
Y scale bar represents 30 FUs and the X scale bar represents 20 seconds. B:
Quantiﬁcation of proportions of cells shows each type of response to
glutamate (N Z 5) in normal conditions (black and white bars) or in the
presence of extracellular EGTA (gray bars). The proportion of responses in
each replicate was calculated, and these values were used for analysis.
Astrocytes transfected with control (ctrl) siRNA tend to show response
types 3 and 4, whereas those transfected with Dlp1 siRNA show a greater
proportion of type 1 responses. No differences are observed between as-
trocytes with ctrl siRNA and Dlp1 (DNM1L) siRNA when EGTA is present and
type 1 responses are not observed. Data are presented as means  SEM.
*P < 0.05 by two-way analysis of variance with Bonferroni correction.
Figure 8 Mitochondrial Ca2þ buffering is impaired during glutamate
stimulation when astrocyte dynamin-like protein 1 (Dlp1) is knocked down.
A: Representative images of the mitochondrial Ca2þ responses to glutamate
in astrocytes transfected with control (ctrl; black line) or Dlp1 (gray line)
siRNA. Traces represent mitochondrial Ca2þ signals relative to baseline from
astrocytes treated with glutamate (black bar). Y scale bar represents 0.01
DF/F, and the X scale bar represents 4 seconds. B: Cumulative probability
plot of the peak amplitude (DF/F) of mitochondrial Ca2þ responses for
astrocytes transfected with ctrl (NZ 7 replicates/473 cells) and Dlp1 siRNA
(N Z 7 replicates/469 cells). P < 0.001 by Kolmogorov-Smirnov test.
Hoekstra et alcurrents in response to glutamate, which were ablated by
chelation of extracellular Ca2þ, suggesting that astrocytic
Dlp1 is important for the regulation of Ca2þ inﬂuxes from
the extracellular space. These results may be due to the
changes in mitochondrial morphological characteristics and
localization. Mitochondria shape intracellular Ca2þ tran-
sients through their buffering capacity,35,36 and they are
transported to the sites of Ca2þ entry to perform efﬁ-
ciently.37,38 As discussed above, knockdown of Dlp1 results
in highly elongated mitochondria that cannot be transported
to their destination, which results in inadequately positioned
mitochondria. Their inadequate positioning results in the
observed dampened mitochondrial buffering and elevated
intracellular Ca2þ. Such changes have the consequence of
decreased function of the glutamate transport system, which
ultimately triggers the events leading to neuronal death. In
this setting, the concentration of extracellular glutamate546would be elevated at the synapse, resulting in an excessive
inﬂux of Ca2þ into neurons via NMDA receptors, as sup-
ported by our ﬁnding that MK-801 attenuated the effects of
insufﬁcient Dlp1. When elevated, neuronal Ca2þ yields
excessive ROS production and activation of several phos-
pholipases, nucleases, and proteases, culminating in
neuronal damage and death (Figure 9, A and B).
Although our results indicate that altered mitochondrial
dynamics in astrocytes results in excitotoxic neuronal
damage from impaired glutamate regulation, there are
several other mechanisms that could contribute to astrocyte
dysfunction and neuronal death that should be mentioned.
One such mechanism could be related to the observed in-
crease in intracellular Ca2þ. In astrocytes, intracellular Ca2þ
can induce exocytosis of glutamate through a process
termed gliotransmission,39 which is regulated by mito-
chondrial handling of Ca2þ.40 Elevated intracellular Ca2þ
could result in increased astrocytic release of glutamate, in
addition to impaired uptake, which would further contribute
to excitotoxicity (Figure 9, A and B). Our proposed mech-
anism (Figure 9) focuses on the activation of metabotrobic
receptors by glutamate, followed by Ca2þ signaling that
proceeds through the ER, the predominant pathway through
which glutamate signals in astrocytes.23 Ionotropic re-
ceptors, which allow extracellular Ca2þ entry directly on
stimulation by glutamate, can contribute toward astrocytic
Ca2þ, but they do not signiﬁcantly contribute towardajp.amjpathol.org - The American Journal of Pathology
Figure 9 Model of proposed mechanism. A:
During neuronal glutamate release under normal
conditions, glutamate binds to its receptors on as-
trocytes, and induces release of Ca2þ from the
endoplasmic reticulum (ER), which causes entry of
extracellular Ca2þ, primarily via metabotropic re-
ceptors, although ionotropic mechanisms may also
participate. Mitochondria buffer cytoplasmic Ca2þ
from each source, astrocytic glutamate uptake oc-
curs, and normal neurotransmission proceeds. B:
When dynamin-like protein 1 (Dlp1) is decreased in
astrocytes, mitochondria are elongated and mis-
localized within astrocytic processes. Mitochondria
are not adequately positioned to buffer the inﬂux of
extracellular Ca2þ, resulting in elevated levels of
intracellular Ca2þ that impair astrocyte-mediated
glutamate uptake. Synaptic levels of glutamate are
increased as a result, which causes neuronal damage
and retraction of the post-synaptic terminal due to
excitotoxicity. Astrocytes also release glutamate in a
Ca2þ-dependent manner in a process called glio-
transmission. Elevated intracellular Ca2þ that results
from decreased Dlp1 could promote excessive
glutamate release and contribute to increased syn-
aptic glutamate and excitotoxicity.
Astrocytic Mitochondrial Dynamics in PDastrocytic responses in comparison to ER-mediated Ca2þ
regulation.23 Nevertheless, extracellular Ca2þ could also
enter through the action of ionotropic receptors, and altered
mitochondrial regulation of extracellular Ca2þ from these
sources could also contribute to the observed changes.
Alterations in mitochondrial dynamics resulting from
Dlp1 knockdown could also affect other aspects of
mitochondrial function that are critical to the cell,
including ATP and ROS production, programmed cell
death, and mitophagy. Through oxidative phosphoryla-
tion, mitochondria produce ATP, with ROS generated as a
by-product. The morphological changes that result from
decreased Dlp1 could affect not only the amounts of ATP
or ROS produced,41 but also the location within the cell
where these products are generated, which could similarlyThe American Journal of Pathology - ajp.amjpathol.orgaffect glutamate transport.42e44 Apoptosis is also heavily
dependent on mitochondrial dynamics and Dlp1.
Apoptotic stimuli promote Dlp1-mediated mitochondrial
fragmentation and a release of cytochrome c, which
results in a caspase cascade and programmed cell death.
This process can be prevented by inhibition or knock-
down of Dlp1.45,46 Because this helps to eliminate un-
healthy cells, decreased astrocytic Dlp1 could result in
lessened removal of impaired astrocytes and reduced
neuronal support and protection. The above-described
impairment of glutamate transport could also result from
decreased mitophagy, a process by which damaged
mitochondria are targeted for degradation by autophagy.
Dlp1 plays a critical role in this process,47 and decreasing
the expression of Dlp1 would increase the number of547
Hoekstra et aldamaged mitochondria in astrocytes or alter the total mito-
chondrial content of cells, further contributing to the decreased
glutamate transport. However, we did not observe changes in
total levels of two mitochondrial proteins (MnSOD and
cytochrome c oxidase; data not shown).
Our study highlights the importance of Dlp1 in astro-
cytes, an aspect that has not been addressed to date; we also
found that Dlp1 was decreased in neurons in PD, which is
also a subject worth discussing. Dlp1 is critical in synaptic
health, because ablation of Dlp1 impairs proper synaptic
pool mobilization and synaptic formation.48,49 Such ﬁndings
may have relevance to neurodegenerative diseases because
Dlp1 is reported to be decreased in Alzheimer disease
brains, similar to our observations in PD. The same study
showed decreased dendritic spines and number of spines
supported by mitochondria after Dlp1 was knocked down in
neurons.22 This occurred in the face of similar elongated
mitochondria, indicating decreased Dlp1 expression in
neurons is detrimental toward their health. Moreover,
overexpression of Dlp1 in neurons not only increased spine
number and synaptic markers, but was protective against
neurotoxic protein oligomers.22 Studies on Pink1 and Park2
(coding for the protein Parkin), two genes responsible for
familial PD, have tied Dlp1 to PD as well. Knockdown of
PINK1 in neurons results in elongated mitochondria, which
can be rescued by overexpression of Dlp1.12 Similar rescue
of mitochondrial morphological characteristics, as well as
other effects, has been observed when Dlp1 is overex-
pressed in Pink1 or Park2 knockout ﬂies.13 Dlp1, therefore,
serves an important role in neuronal health by promoting
adequate mitochondrial positioning within neurons to sup-
port proper function, and decreased expression could have
detrimental effects. This would mean that the decrease in
neuronal Dlp1 in the setting of PD likely represents a pro-
cess that contributes to neuronal dysfunction and/or death.
In summary, our results show that Dlp1 was decreased in
several cell types and multiple brain regions in PD. More
important, we demonstrated that astrocyte dysfunction sec-
ondary to decreased Dlp1 expression can contribute to
neurodegeneration, in part via excitotoxicity. Finally, our
data strongly suggest that astrocytic dysfunction due to Dlp1
reduction is coupled to compromised mitochondrial ability
to buffer cytosolic Ca2þ, which leads to excessive accu-
mulation of extracellular glutamate. Dlp1 also decreases in
brain regions without apparent neurodegeneration, which
indicates a relatively early event. Correcting this deﬁciency
might be an attractive approach to treat PD patients, espe-
cially at early stages.Acknowledgments
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